MX2024008530A - Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea. - Google Patents
Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea.Info
- Publication number
- MX2024008530A MX2024008530A MX2024008530A MX2024008530A MX2024008530A MX 2024008530 A MX2024008530 A MX 2024008530A MX 2024008530 A MX2024008530 A MX 2024008530A MX 2024008530 A MX2024008530 A MX 2024008530A MX 2024008530 A MX2024008530 A MX 2024008530A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- treatment
- methods
- eye disease
- thyroid eye
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263266548P | 2022-01-07 | 2022-01-07 | |
| PCT/US2023/060206 WO2023133485A2 (en) | 2022-01-07 | 2023-01-06 | Compositions and methods for treatment of thyroid eye disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024008530A true MX2024008530A (es) | 2024-09-26 |
Family
ID=87074297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008530A MX2024008530A (es) | 2022-01-07 | 2023-01-06 | Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240360227A1 (https=) |
| EP (1) | EP4460524A4 (https=) |
| JP (1) | JP2025503339A (https=) |
| KR (1) | KR20240130134A (https=) |
| CN (1) | CN118679187A (https=) |
| AU (1) | AU2023205915A1 (https=) |
| MX (1) | MX2024008530A (https=) |
| WO (1) | WO2023133485A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119792512A (zh) | 2020-10-14 | 2025-04-11 | 维里迪安治疗公司 | 用于治疗甲状腺眼病的组合物和方法 |
| TW202320850A (zh) | 2021-08-10 | 2023-06-01 | 美商維里迪恩醫療股份有限公司 | 用於治療甲狀腺眼病之組合物、劑量及方法 |
| WO2025014774A1 (en) | 2023-07-07 | 2025-01-16 | Viridian Therapeutics, Inc. | Methods of treating active and chronic thyroid eye disease |
| WO2025051229A1 (zh) * | 2023-09-08 | 2025-03-13 | 北京拓界生物医药科技有限公司 | Igf-1r及tshr结合蛋白及其医药用途 |
| WO2025136985A1 (en) * | 2023-12-17 | 2025-06-26 | Viridian Therapeutics, Inc. | Compositions, doses, and methods for treatment of thyroid eye disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| WO2007062037A2 (en) * | 2005-11-21 | 2007-05-31 | Laboratoires Serono Sa | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
| WO2013169611A1 (en) * | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Compositions and methods for treating breast cancer |
-
2023
- 2023-01-06 WO PCT/US2023/060206 patent/WO2023133485A2/en not_active Ceased
- 2023-01-06 JP JP2024540899A patent/JP2025503339A/ja active Pending
- 2023-01-06 KR KR1020247026159A patent/KR20240130134A/ko active Pending
- 2023-01-06 CN CN202380021098.6A patent/CN118679187A/zh active Pending
- 2023-01-06 MX MX2024008530A patent/MX2024008530A/es unknown
- 2023-01-06 AU AU2023205915A patent/AU2023205915A1/en active Pending
- 2023-01-06 EP EP23737768.4A patent/EP4460524A4/en active Pending
-
2024
- 2024-07-01 US US18/760,539 patent/US20240360227A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023205915A1 (en) | 2024-07-18 |
| EP4460524A4 (en) | 2026-03-04 |
| KR20240130134A (ko) | 2024-08-28 |
| CN118679187A (zh) | 2024-09-20 |
| JP2025503339A (ja) | 2025-02-03 |
| WO2023133485A3 (en) | 2023-08-10 |
| WO2023133485A2 (en) | 2023-07-13 |
| EP4460524A2 (en) | 2024-11-13 |
| US20240360227A1 (en) | 2024-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004280A (es) | Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea. | |
| MX2024008530A (es) | Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea. | |
| CA3242661A1 (en) | Compositions and methods for treatment of thyroid eye disease | |
| PH12022550509A1 (en) | Anti-cd73 antibodies | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
| ZA202309516B (en) | Anti-ccr8 antibodies | |
| WO2022132596A3 (en) | Tissue-specific antigens for cancer immunotherapy | |
| MX2024012567A (es) | Composiciones farmaceuticas de anticuerpos biespecificos anti-cd20/anti-cd3 y metodos de uso | |
| MX2023010278A (es) | Metodos para el tratamiento de la enfermedad ocular tiroidea. | |
| JOP20210245A1 (ar) | طرق لعلاج الداء النشواني من النوع خفيف السلسلة | |
| AU2016348418A8 (en) | Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same | |
| MX2020011176A (es) | Metodos para tratar cancer con una combinacion de un anticuerpo anti-molecula de muerte programada 1 y un conjugado de anticuerpo anti-factor tisular-medicamento. | |
| WO2021207433A3 (en) | Epitopes of sars-cov-2 neutralizing antibodies | |
| MX2023005841A (es) | Anticuerpos anti-marco y usos de estos. | |
| EP4640698A3 (en) | Antibodies to mucin-16 and methods of use thereof | |
| MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. | |
| MX2025005092A (es) | Anticuerpo anti-trem2 y usos del mismo | |
| MX2023012300A (es) | Anticuerpos humanos contra artemina y metodos de uso de estos. | |
| MX2024001304A (es) | Composiciones y metodos para anticuerpos anti-pacap. | |
| WO2021257695A3 (en) | Methods and compositions related to neutralizing antibodies against human coronavirus | |
| WO2022082030A3 (en) | Antigen-binding proteins and related methods of use | |
| CA3242672A1 (en) | Compositions and methods for treatment of thyroid eye disease | |
| WO2020186111A3 (en) | Vista-binding antibodies and uses thereof |